{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Type+1+%28HIV-1%29&page=7", "query": { "condition": "Human Immunodeficiency Virus Type 1 (HIV-1)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1082, "total_pages": 109, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Type+1+%28HIV-1%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Type+1+%28HIV-1%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:04:14.019Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03934541", "title": "Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MPER-656 Liposome Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo for MPER-656 Liposome Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2019-08-26", "completion_date": "2021-05-26", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934541" }, { "nct_id": "NCT02397694", "title": "Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "BIC", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "BIC Placebo", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-03-23", "completion_date": "2019-02-27", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397694" }, { "nct_id": "NCT00131677", "title": "Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 400, "start_date": "2005-02", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2014-03-10", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 3, "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131677" }, { "nct_id": "NCT00016588", "title": "Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016588" }, { "nct_id": "NCT00002235", "title": "A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 6, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 5, "location_summary": "Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Hampton", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002235" }, { "nct_id": "NCT00098293", "title": "Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "Maraviroc + Zidovudine/Lamivudine", "type": "DRUG" }, { "name": "Efavirenz + Zidovudine/Lamivudine", "type": "DRUG" }, { "name": "Maraviroc (UK-427,857) + Zidovudine/Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 916, "start_date": "2004-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2013-10-09", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098293" }, { "nct_id": "NCT01388543", "title": "Genetics and HIV-1 Protease Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 31, "start_date": "2006-09", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01388543" }, { "nct_id": "NCT01906255", "title": "Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV" ], "interventions": [], "intervention_types": [], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10577, "start_date": "2013-10-07", "completion_date": "2021-04-27", "has_results": false, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 1, "location_summary": "Foster City, California", "locations": [ { "city": "Foster City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01906255" }, { "nct_id": "NCT02386098", "title": "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "BMS-955176", "type": "DRUG" }, { "name": "Atazanavir (ATV)", "type": "DRUG" }, { "name": "Ritonavir (RTV)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Tenofovir (TDF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2015-07-08", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 16, "location_summary": "Beverly Hills, California • Los Angeles, California • Palm Springs, California + 13 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02386098" }, { "nct_id": "NCT00612898", "title": "Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "apricitabine", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avexa", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2008-02", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-01-23", "last_synced_at": "2026-10-14T16:04:14.019Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612898" } ] }